metformin has been researched along with thiophenes in 64 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (1.56) | 18.2507 |
| 2000's | 1 (1.56) | 29.6817 |
| 2010's | 54 (84.38) | 24.3611 |
| 2020's | 8 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Hussar, DA | 1 |
| Adler, A; Camp, HS; Cao, N; Chiou, W; Cool, B; Dickinson, R; Frevert, E; Gagne, G; Iyengar, R; Jung, P; Kifle, L; Kym, P; Marsh, K; Perham, M; Zhao, G; Zinker, B | 1 |
| Hosoi, Y; Kanamaru, T; Konno, T; Nakagami, H; Tajiri, S; Yada, S; Yoshida, K | 1 |
| Fernandez-Millan, E; Leclerc, I; Morris, C; Nyirenda, M; Rutter, GA; Sun, G | 1 |
| Arun, B; Brown, PH; Castiglione, M; Cuzick, J; DeCensi, A; Dunn, B; Forbes, JF; Glaus, A; Howell, A; Vogel, V; von Minckwitz, G; Zwierzina, H | 1 |
| Cufí, S; López-Otín, C; Martin, AG; Martin-Castillo, B; Menendez, JA; Oliveras-Ferraros, C; Quirós, PM; Ruiz de Galarreta, E; Vazquez-Martin, A; Vellon, L | 1 |
| Aggarwal, N; Arbit, D; Canovatchel, W; Capuano, G; Polidori, D; Rosenstock, J; Usiskin, K; Zhao, Y | 1 |
| Capuano, G; Nicolle, LE; Usiskin, K; Ways, K | 1 |
| Collins, C; Kadokura, T; Smulders, RA; van Bruijnsvoort, M; van Dijk, J; Veltkamp, SA | 1 |
| Atar, D; Serebruany, VL | 1 |
| Dhanjal, P; Ferrannini, E; Fonseca, VA; Houzer, A; Wilding, JP; Wilpshaar, W | 1 |
| Canovatchel, W; Fu, M; Gross, JL; Guarisco, M; Kawaguchi, M; Meininger, G; Rosenstock, J; Schernthaner, G; Yee, J | 1 |
| Arias, P; Balis, DA; Canovatchel, W; Cefalu, WT; Leiter, LA; Meininger, G; Niskanen, L; Xie, J; Yoon, KH | 1 |
| Burris, TP; Fernandez-Ruiz, R; Figueroa, AL; Gomis, R; Marroquí, L; Merino, B; Nadal, A; Quesada, I; Vieira, E | 1 |
| Canovatchel, W; Davidson, J; Januszewicz, A; Lavalle-González, FJ; Meininger, G; Qiu, R; Tong, C | 1 |
| Black, S; Canovatchel, W; Charpentier, G; González-Gálvez, G; Hollander, P; Law, G; Mathieu, C; Meininger, G; Usiskin, K; Vercruysse, F; Wilding, JP | 1 |
| Capuano, G; Fung, A; Nicolle, LE; Usiskin, K | 1 |
| Seufert, J | 1 |
| Schnell, O | 1 |
| Bailey, RA; Blonde, L; Damaraju, CV; Martin, SC; Meininger, GE; Rupnow, MF | 1 |
| Forst, T; Goldenberg, R; Guthrie, R; Meininger, G; Stein, P; Vijapurkar, U; Yee, J | 1 |
| Ferrannini, E; Mari, A; Polidori, D | 1 |
| Goto, K; Kashiwagi, A; Kazuta, K; Ueyama, E; Utsuno, A; Yoshida, S | 1 |
| Farrell, K; Heise, T; Natarajan, J; Plum-Mörschel, L; Polidori, D; Rothenberg, P; Sha, S; Sica, D; Wang, SS | 1 |
| Dou, J; Lu, J; Zhang, Q | 1 |
| Artis, E; Berg, JK; Devineni, D; Morrow, L; Polidori, D; Rusch, S; Stein, P; Vaccaro, N | 1 |
| Dieu Van, NK; Han, P; Ji, L; Liu, Y; Meininger, G; Qiu, R; Vijapurkar, U; Yang, G | 1 |
| Arias, P; Balis, DA; Canovatchel, W; Langslet, G; Leiter, LA; Meininger, G; Millington, D; Vercruysse, F; Xie, J; Yoon, KH | 1 |
| Blagih, J; Coelho, PP; Griss, T; Jones, RG; Vincent, EE; Viollet, B | 1 |
| Bode, B; Fung, A; Harris, S; Meininger, G; Stenlöf, K; Sullivan, D; Usiskin, K | 1 |
| Devineni, D; Murphy, J; Stieltjes, H; Wajs, E; Wang, SS | 1 |
| Barreto-Torres, G; Basnakian, AG; Hernandez, JS; Jang, S; Javadov, S; Rodríguez-Muñoz, AR; Torres-Ramos, CA | 1 |
| Andjelkovic, M; Buse, JB; Durrwell, L; El Azzouzi, B; Henry, RR; Herz, M; Jaekel, K; Mingrino, R; Wu, H | 1 |
| Rupprecht, H | 1 |
| Chung, FF; Hii, LW; Ho, GF; Leong, CO; Malik, RA; Ng, CH; See, MH; Soo, JS; Taib, NA; Tan, BS; Tan, SH; Teh, YC; Teo, SH; Yip, CH | 1 |
| Abe, M; Amachi, R; Hanson, DJ; Harada, T; Hiasa, M; Horikawa, K; Itoh, K; Matsumoto, T; Miki, H; Nakamura, S; Oda, A; Teramachi, J; Tsuji, D | 1 |
| Jia, Y; Lee, JH; Lee, SJ; Seo, WD; Wu, C | 1 |
| Kashiwagi, A; Kawamuki, K; Kazuta, K; Kosakai, Y; Nakamura, I; Satomi, H; Takahashi, H; Ueyama, E; Yoshida, S | 1 |
| Cha, BS; Chuang, LM; Kokubo, S; Lu, CH; Min, KW; Yoshida, S | 1 |
| Bailey, RA; Blonde, L; Meininger, G; Patel, CA; Vijapurkar, U | 1 |
| Asiedu, MN; Dib-Hajj, SD; Dussor, G; Han, C; Price, TJ; Waxman, SG | 1 |
| Ma, A; Wang, J; Zhao, M; Zhu, H | 1 |
| Hashimoto, N; Horikoshi, T; Ishikawa, K; Ishikawa, T; Kobayashi, K; Koshizaka, M; Kuribayashi, N; Nagashima, K; Sato, Y; Shimofusa, R; Takahashi, S; Takemoto, M; Tatsuno, I; Terano, T; Uchida, D; Yokote, K | 1 |
| Bizjak, M; Dolinar, K; Malavašič, P; Pavlin, M; Pirkmajer, S; Pohar, J | 1 |
| Arunan, V; Beloueche-Babari, M; Casals Galobart, T; Chung, YL; Eykyn, TR; Koniordou, M; Leach, MO; Parkes, HG; Smith, PD; Wantuch, S | 1 |
| Boudaba, N; Foretz, M; Huet, C; Marion, A; Pierre, R; Viollet, B | 1 |
| Baik, S; Cha, BS; Chon, S; Chung, CH; Han, KA; Jung, CH; Kim, DS; Lee, IK; Lee, KW; Lee, MK; Lim, S; Park, KS; Park, S; Sakatani, T; Yoon, KH | 1 |
| Miyamoto, L | 1 |
| Agturk, G; Dogan, H; Dokuyucu, R; Karateke, A; Ozgur, T; Tas, ZA; Tumer, C; Tutuk, O | 1 |
| Orlova, VL; Shestakova, MV; Tretter, R; Verbovoy, AF; Wilding, JPH; Wilpshaar, W | 1 |
| Cui, A; Fan, JG; Fang, J; Gao, J; Han, Y; Hu, Z; Li, J; Li, Y; Liu, Y; Liu, Z; Ma, F; Song, BL; Wei, C; Xue, Y; Yu, Y; Zhang, F; Zhao, Z | 1 |
| Baba, Y; Hashimoto, N; Hattori, A; Horikoshi, T; Ide, K; Ide, S; Ishibashi, R; Ishikawa, K; Ishikawa, T; Kitamoto, T; Kobayashi, A; Kobayashi, K; Koshizaka, M; Maezawa, Y; Nagashima, K; Nakamura, S; Newby, LK; Ogino, J; Ohara, E; Onishi, S; Sakamoto, K; Sato, Y; Shimada, F; Shimofusa, R; Shoji, M; Takahashi, S; Takemoto, M; Tokuyama, H; Uchida, D; Yamaga, M; Yokoh, H; Yokote, K | 2 |
| Dai, J; Peng, XW; Zhang, L; Zhou, HH | 1 |
| Chen, M; Chen, W; Chen, Y; Li, P; Wang, B; Wang, G | 1 |
| Abrams, G; Adolfsson, E; Agarwal, PK; Akkan, AG; Al Alhareth, NS; Alves, VGL; Armentano, R; Bahroos, E; Baig, M; Baldridge, KK; Barman, S; Bartolucci, C; Basit, A; Bertoli, SV; Bian, L; Bigatti, G; Bobenko, AI; Boix, PP; Bokulic, T; Bolink, HJ; Borowiec, J; Bulski, W; Burciaga, J; Butt, NS; Cai, AL; Campos, AM; Cao, G; Cao, Y; Čapo, I; Caruso, ML; Chao, CT; Cheatum, CM; Chelminski, K; Chen, AJW; Chen, C; Chen, CH; Chen, D; Chen, G; Chen, H; Chen, LH; Chen, R; Chen, RX; Chen, X; Cherdtrakulkiat, R; Chirvony, VS; Cho, JG; Chu, K; Ciurlino, D; Coletta, S; Contaldo, G; Crispi, F; Cui, JF; D'Esposito, M; de Biase, S; Demir, B; Deng, W; Deng, Z; Di Pinto, F; Domenech-Ximenos, B; Dong, G; Drácz, L; Du, XJ; Duan, LJ; Duan, Y; Ekendahl, D; Fan, W; Fang, L; Feng, C; Followill, DS; Foreman, SC; Fortunato, G; Frew, R; Fu, M; Gaál, V; Ganzevoort, W; Gao, DM; Gao, X; Gao, ZW; Garcia-Alvarez, A; Garza, MS; Gauthier, L; Gazzaz, ZJ; Ge, RS; Geng, Y; Genovesi, S; Geoffroy, V; Georg, D; Gigli, GL; Gong, J; Gong, Q; Groeneveld, J; Guerra, V; Guo, Q; Guo, X; Güttinger, R; Guyo, U; Haldar, J; Han, DS; Han, S; Hao, W; Hayman, A; He, D; Heidari, A; Heller, S; Ho, CT; Ho, SL; Hong, SN; Hou, YJ; Hu, D; Hu, X; Hu, ZY; Huang, JW; Huang, KC; Huang, Q; Huang, T; Hwang, JK; Izewska, J; Jablonski, CL; Jameel, T; Jeong, HK; Ji, J; Jia, Z; Jiang, W; Jiang, Y; Kalumpha, M; Kang, JH; Kazantsev, P; Kazemier, BM; Kebede, B; Khan, SA; Kiss, J; Kohen, A; Kolbenheyer, E; Konai, MM; Koniarova, I; Kornblith, E; Krawetz, RJ; Kreouzis, T; Kry, SF; Laepple, T; Lalošević, D; Lan, Y; Lawung, R; Lechner, W; Lee, KH; Lee, YH; Leonard, C; Li, C; Li, CF; Li, CM; Li, F; Li, J; Li, L; Li, S; Li, X; Li, Y; Li, YB; Li, Z; Liang, C; Lin, J; Lin, XH; Ling, M; Link, TM; Liu, HH; Liu, J; Liu, M; Liu, W; Liu, YP; Lou, H; Lu, G; Lu, M; Lun, SM; Ma, Z; Mackensen, A; Majumdar, S; Martineau, C; Martínez-Pastor, JP; McQuaid, JR; Mehrabian, H; Meng, Y; Miao, T; Miljković, D; Mo, J; Mohamed, HSH; Mohtadi, M; Mol, BWJ; Moosavi, L; Mosdósi, B; Nabu, S; Nava, E; Ni, L; Novakovic-Agopian, T; Nyamunda, BC; Nyul, Z; Önal, B; Özen, D; Özyazgan, S; Pajkrt, E; Palazon, F; Park, HW; Patai, Á; Patai, ÁV; Patzke, GR; Payette, G; Pedoia, V; Peelen, MJCS; Pellitteri, G; Peng, J; Perea, RJ; Pérez-Del-Rey, D; Popović, DJ; Popović, JK; Popović, KJ; Posecion, L; Povall, J; Prachayasittikul, S; Prachayasittikul, V; Prat-González, S; Qi, B; Qu, B; Rakshit, S; Ravelli, ACJ; Ren, ZG; Rivera, SM; Salo, P; Samaddar, S; Samper, JLA; Samy El Gendy, NM; Schmitt, N; Sekerbayev, KS; Sepúlveda-Martínez, Á; Sessolo, M; Severi, S; Sha, Y; Shen, FF; Shen, X; Shen, Y; Singh, P; Sinthupoom, N; Siri, S; Sitges, M; Slovak, JE; Solymosi, N; Song, H; Song, J; Song, M; Spingler, B; Stewart, I; Su, BL; Su, JF; Suming, L; Sun, JX; Tantimavanich, S; Tashkandi, JM; Taurbayev, TI; Tedgren, AC; Tenhunen, M; Thwaites, DI; Tibrewala, R; Tomsejm, M; Triana, CA; Vakira, FM; Valdez, M; Valente, M; Valentini, AM; Van de Winckel, A; van der Lee, R; Varga, F; Varga, M; Villarino, NF; Villemur, R; Vinatha, SP; Vincenti, A; Voskamp, BJ; Wang, B; Wang, C; Wang, H; Wang, HT; Wang, J; Wang, M; Wang, N; Wang, NC; Wang, Q; Wang, S; Wang, X; Wang, Y; Wang, Z; Wen, N; Wesolowska, P; Willis, M; Wu, C; Wu, D; Wu, L; Wu, X; Wu, Z; Xia, JM; Xia, X; Xia, Y; Xiao, J; Xiao, Y; Xie, CL; Xie, LM; Xie, S; Xing, Z; Xu, C; Xu, J; Yan, D; Yan, K; Yang, S; Yang, X; Yang, XW; Ye, M; Yin, Z; Yoon, N; Yoon, Y; Yu, H; Yu, K; Yu, ZY; Zhang, B; Zhang, GY; Zhang, H; Zhang, J; Zhang, M; Zhang, Q; Zhang, S; Zhang, W; Zhang, X; Zhang, Y; Zhang, YW; Zhang, Z; Zhao, D; Zhao, F; Zhao, P; Zhao, W; Zhao, Z; Zheng, C; Zhi, D; Zhou, C; Zhou, FY; Zhu, D; Zhu, J; Zhu, Q; Zinyama, NP; Zou, M; Zou, Z | 1 |
| Chen, X; Ouyang, J; Wang, H; Yang, J; Yao, G | 1 |
| Callan, E; Entringer, B; Joshi, A; Konduri, GG; Michalkiewicz, T; Parchur, AK; Rana, U; Teng, RJ | 1 |
| Kurozumi, A; Okada, Y; Tanaka, Y | 1 |
| Fujihara, K; Furukawa, K; H Yamada, M; Hatta, M; Ikarashi, T; Iwanaga, M; Katagiri, T; Kitazawa, M; Matsunaga, S; Sone, H; Suzuki, H; Tanaka, S; Yamada, T; Yamamoto, M | 1 |
| Engel, SS; Kadowaki, T; Kaku, K; Kaufman, KD; O'Neill, EA; Okamoto, T; Sato, A; Seino, Y; Shirakawa, M | 2 |
| An, H; An, X; Chen, Y; Dai, X; Guan, S; Huang, B; Huang, Q; Liang, L; Lu, M; Lu, X; Nie, H; Wang, H; Wang, J; Wang, Z; Zhang, H | 1 |
| Borutinskaitė, V; Navakauskienė, R; Skliutė, G; Valiulienė, G; Vitkevičienė, A | 1 |
9 review(s) available for metformin and thiophenes
| Article | Year |
|---|---|
Preventive therapy for breast cancer: a consensus statement.
Topics: Anastrozole; Androstadienes; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Consensus Development Conferences as Topic; Diphosphonates; Estrogen Receptor Modulators; Expert Testimony; Female; Fenretinide; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Metformin; Nitriles; Norpregnenes; Piperidines; Premenopause; Pyrrolidines; Raloxifene Hydrochloride; Retinoids; Selective Estrogen Receptor Modulators; Tamoxifen; Tetrahydronaphthalenes; Thiophenes; Triazoles | 2011 |
[Oral add-on therapy to metformin in type 2 diabetes mellitus: a direct comparison beween canagliflozin and glimepiride].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Blood Glucose; Canagliflozin; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Endpoint Determination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Intra-Abdominal Fat; Male; Metformin; Middle Aged; Randomized Controlled Trials as Topic; Sulfonylurea Compounds; Thiophenes | 2014 |
[Oral add-on therapy to metformin in type 2 diabetes mellitus: a direct comparison between canagliflozin and sitagliptin].
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Blood Glucose; Blood Pressure; Body Weight; Canagliflozin; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dose-Response Relationship, Drug; Drug Therapy, Combination; Endpoint Determination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pyrazines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Thiophenes; Triazoles; Young Adult | 2014 |
Combinational therapy with metformin and sodium-glucose cotransporter inhibitors in management of type 2 diabetes: systematic review and meta-analyses.
Topics: Adult; Aged; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Canagliflozin; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2014 |
[The role of SGLT-2 inhibitors in the treatment of type 2 diabetes].
Topics: Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2015 |
[AMPK as a Metabolic Intersection between Diet and Physical Exercise].
Topics: Aminoimidazole Carboxamide; AMP-Activated Protein Kinases; Biphenyl Compounds; Diet; Drug Discovery; Eating; Exercise; Exercise Therapy; Humans; Hypoglycemic Agents; Isoenzymes; Metabolic Diseases; Metformin; Molecular Targeted Therapy; Muscle Contraction; Pyrones; Ribonucleosides; Thiophenes | 2018 |
[Advances on the anti-inflammatory and protective effect of AMPK activators].
Topics: Adiponectin; Aminoimidazole Carboxamide; AMP-Activated Protein Kinases; Animals; Biphenyl Compounds; Enzyme Activation; Inflammation; Metformin; Pyrones; Thiophenes | 2019 |
Efficacy and safety of ipragliflozin as add-on to metformin for type 2 diabetes: a meta-analysis of double-blind randomized controlled trials.
Topics: Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Randomized Controlled Trials as Topic; Thiophenes | 2019 |
Topics: Acetylcholine; Acinetobacter baumannii; Actinobacteria; Action Potentials; Adalimumab; Adaptation, Physiological; Adipates; Administration, Oral; Adolescent; Adrenal Glands; Adsorption; Adult; Aged; Aged, 80 and over; Aging; AIDS-Related Opportunistic Infections; Aldosterone; Amino Acids; Ammonia; Amoxicillin; AMP-Activated Protein Kinases; Animals; Antacids; Anti-Bacterial Agents; Antineoplastic Agents; Antirheumatic Agents; Apgar Score; Area Under Curve; ARNTL Transcription Factors; Arterial Pressure; Arthritis, Juvenile; Athletes; Attention; Biodegradation, Environmental; Biofilms; Biofuels; Biological Therapy; Biomass; Biomimetic Materials; Bioreactors; Birth Weight; Bismuth; Blood Flow Velocity; Bone and Bones; Brain Injuries, Traumatic; Calcium; Calcium Channels; Capsaicin; Carbon; Carcinoma, Hepatocellular; Cardiomegaly, Exercise-Induced; Cartilage; Cartilage, Articular; Case-Control Studies; Catalysis; Cats; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cell Death; Cell Differentiation; Cell Line, Tumor; Cell Membrane; Charcoal; Chemokine CCL2; Child; Child, Preschool; Chondrogenesis; Chronic Disease; Circadian Clocks; Circadian Rhythm Signaling Peptides and Proteins; Clarithromycin; Coccidioides; Coccidioidomycosis; Cognitive Behavioral Therapy; Coinfection; Color; Coloring Agents; Computer Simulation; Computers, Molecular; Consensus; Corticosterone; Cyclic AMP Response Element-Binding Protein; Cytochrome P-450 Enzyme System; Death, Sudden, Cardiac; Density Functional Theory; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Dialysis Solutions; Disease Models, Animal; Dogs; Dopamine Agonists; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Drug Resistance, Bacterial; Drug Therapy, Combination; Electrocardiography; Electrocardiography, Ambulatory; Electrolytes; Endocardium; Endocrine Disruptors; Endocytosis; Endoscopy, Gastrointestinal; Escherichia coli Proteins; Esters; Evolution, Molecular; Executive Function; Feasibility Studies; Female; Ferric Compounds; Fluorescence; Fluorescent Dyes; Fluorine Radioisotopes; Frailty; Free Radical Scavengers; Gabapentin; Geriatric Assessment; Glucaric Acid; Glucocorticoids; Glucose; Glucose Metabolism Disorders; Halogenated Diphenyl Ethers; Heart Rate; Heart Ventricles; HEK293 Cells; Helicobacter Infections; Helicobacter pylori; Hep G2 Cells; Hepatocytes; Humans; Hungary; Hydrogen Sulfide; Hydrogen-Ion Concentration; Immunologic Factors; Immunomodulation; Immunosuppressive Agents; Independent Living; Indocyanine Green; Infant; Infant Formula; Infant Mortality; Infant, Newborn; Infant, Newborn, Diseases; Inflorescence; Insulin Resistance; Insulins; International Agencies; Iron; Isotonic Solutions; Kidney Failure, Chronic; Kinetics; Lactones; Leukocytes, Mononuclear; Liver Neoplasms; Macular Edema; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Magnetosomes; Male; Medical Audit; Mesenchymal Stem Cells; Metabolic Syndrome; Metformin; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Nude; Middle Aged; Molecular Conformation; Molecular Targeted Therapy; Motor Activity; Multiple Sclerosis; Mycophenolic Acid; Netherlands; Neuropsychological Tests; Nuclear Energy; Organs at Risk; Osteoarthritis; Osteoarthritis, Hip; Oxidation-Reduction; Palladium; Pericardium; Perinatal Death; Peritoneal Dialysis; Phantoms, Imaging; Pharmaceutical Preparations; Phospholipids; Phosphorylation; Physical Conditioning, Human; Physical Endurance; Pilot Projects; Polyketides; Polymers; Positron-Emission Tomography; Postoperative Period; Potassium; Powders; Pramipexole; Predictive Value of Tests; Pregabalin; Pregnancy; Pregnancy Outcome; Protein Structure, Secondary; Proton Pump Inhibitors; Puberty; Pulmonary Circulation; Quality Assurance, Health Care; Quantum Dots; Radiometry; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Intensity-Modulated; Rats, Sprague-Dawley; Receptors, CCR2; Receptors, Transferrin; Regeneration; Registries; Renal Insufficiency, Chronic; Reproducibility of Results; Research Design; Restless Legs Syndrome; Retina; Retinoid X Receptor alpha; Retrospective Studies; Rhenium; Risk Factors; RNA, Messenger; Severity of Illness Index; Sex Factors; Sodium; Sodium Fluoride; Solvents; Spectrometry, Fluorescence; Spectroscopy, Fourier Transform Infrared; Stereoisomerism; Stroke; Structure-Activity Relationship; Tachycardia, Ventricular; Tetracycline; Tetrahydrofolate Dehydrogenase; Tetrahydronaphthalenes; Thermodynamics; Thiophenes; Time Factors; Tinidazole; Tomography, Optical Coherence; Tomography, X-Ray Computed; Topiramate; Toxoplasma; Toxoplasmosis, Cerebral; Transferrin; Treatment Outcome; Up-Regulation; Upper Extremity; Uremia; Uveitis; Vascular Remodeling; Ventricular Fibrillation; Ventricular Function, Left; Ventricular Function, Right; Ventricular Remodeling; Verapamil; Veterans; Visual Acuity; Vitrectomy; Water Pollutants, Chemical; Zea mays; Zirconium | 2019 |
30 trial(s) available for metformin and thiophenes
| Article | Year |
|---|---|
Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes.
Topics: Adolescent; Adult; Aged; Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Treatment Outcome; Weight Loss; Young Adult | 2012 |
Effect of canagliflozin, a sodium glucose co-transporter 2 (SGLT2) inhibitor, on bacteriuria and urinary tract infection in subjects with type 2 diabetes enrolled in a 12-week, phase 2 study.
Topics: Bacteriuria; Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucosides; Glycosuria; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Triazoles; Urinary Tract Infections | 2012 |
Combination treatment with ipragliflozin and metformin: a randomized, double-blind, placebo-controlled study in patients with type 2 diabetes mellitus.
Topics: Adult; Aged; Area Under Curve; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Interactions; Drug Monitoring; Drug Therapy, Combination; Europe; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Metabolic Clearance Rate; Metformin; Middle Aged; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Time Factors; Treatment Outcome | 2012 |
Efficacy and safety of ipragliflozin in patients with type 2 diabetes inadequately controlled on metformin: a dose-finding study.
Topics: Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Europe; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Thiophenes; Time Factors; Treatment Outcome; United States | 2013 |
Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial.
Topics: Aged; Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiophenes; Treatment Outcome; Triazoles | 2013 |
Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Canagliflozin; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Sulfonylurea Compounds; Thiophenes; Treatment Outcome; Young Adult | 2013 |
Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial.
Topics: Adolescent; Aged; Aged, 80 and over; Blood Glucose; Blood Pressure; Body Weight; Canagliflozin; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fasting; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Lipids; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Thiophenes; Treatment Outcome; Triazoles | 2013 |
Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Blood Glucose; Blood Pressure; Canagliflozin; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin-Secreting Cells; Lipid Metabolism; Male; Metformin; Middle Aged; Sulfonylurea Compounds; Thiophenes; Treatment Outcome; Weight Loss; Young Adult | 2013 |
Urinary tract infection in randomized phase III studies of canagliflozin, a sodium glucose co-transporter 2 inhibitor.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Blood Glucose; Blood Pressure; Body Weight; Canagliflozin; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incidence; Male; Metformin; Middle Aged; Recurrence; Sodium-Glucose Transporter 2 Inhibitors; Sulfonylurea Compounds; Thiophenes; Urinary Tract Infections; Young Adult | 2014 |
Attainment of diabetes-related quality measures with canagliflozin versus sitagliptin.
Topics: Aged; Blood Pressure; Body Mass Index; Canagliflozin; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pyrazines; Quality Indicators, Health Care; Racial Groups; Sitagliptin Phosphate; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Triazoles | 2014 |
Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone.
Topics: Blood Glucose; Blood Pressure; Canagliflozin; Candidiasis; Diabetes Mellitus, Type 2; Diuretics, Osmotic; Double-Blind Method; Drug Therapy, Combination; Female; Genital Diseases, Female; Genital Diseases, Male; Glucosides; Humans; Hypoglycemic Agents; Lipids; Male; Metformin; Middle Aged; Pioglitazone; Pyrazines; Sitagliptin Phosphate; Thiazolidinediones; Thiophenes; Treatment Outcome; Triazoles; Weight Loss | 2014 |
Canagliflozin, a sodium glucose co-transporter 2 inhibitor, improves model-based indices of beta cell function in patients with type 2 diabetes.
Topics: Adult; Aged; Blood Glucose; C-Peptide; Canagliflozin; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucosides; Humans; Insulin-Secreting Cells; Least-Squares Analysis; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Sodium-Glucose Transporter 2; Sulfonylurea Compounds; Thiophenes; Time Factors; Triazoles | 2014 |
Ipragliflozin in combination with metformin for the treatment of Japanese patients with type 2 diabetes: ILLUMINATE, a randomized, double-blind, placebo-controlled study.
Topics: Aged; Asian People; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Placebos; Thiophenes | 2015 |
Effect of the sodium glucose co-transporter 2 inhibitor canagliflozin on plasma volume in patients with type 2 diabetes mellitus.
Topics: Adult; Aged; Antihypertensive Agents; Blood Glucose; Blood Pressure; Body Weight; Canagliflozin; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dose-Response Relationship, Drug; Drug Therapy, Combination; Fasting; Female; Glucosides; Glycated Hemoglobin; Humans; Hypertension; Hypoglycemic Agents; Kidney; Male; Metformin; Middle Aged; Plasma Volume; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Treatment Outcome; Water-Electrolyte Balance; Weight Loss | 2014 |
Canagliflozin, a sodium glucose co-transporter 2 inhibitor, reduces post-meal glucose excursion in patients with type 2 diabetes by a non-renal mechanism: results of a randomized trial.
Topics: Blood Glucose; Canagliflozin; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Fasting; Female; Glucose; Glucosides; Humans; Kidney; Male; Metformin; Middle Aged; Postprandial Period; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2014 |
Canagliflozin in Asian patients with type 2 diabetes on metformin alone or metformin in combination with sulphonylurea.
Topics: Aged; Canagliflozin; China; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Resistance; Drug Resistance, Multiple; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Malaysia; Male; Membrane Transport Modulators; Metformin; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Sulfonylurea Compounds; Thiophenes; Vietnam | 2015 |
Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: a randomized, double-blind, phase 3 study.
Topics: Blood Glucose; Body Weight; Canagliflozin; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Sulfonylurea Compounds; Thiophenes; Time Factors; Treatment Outcome; Weight Loss | 2015 |
Long-term efficacy and safety of canagliflozin over 104 weeks in patients aged 55-80 years with type 2 diabetes.
Topics: Aged; Aged, 80 and over; Blood Glucose; Blood Pressure; Body Weight; Canagliflozin; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diuresis; Double-Blind Method; Fasting; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Mycoses; Osmolar Concentration; Thiophenes; Urinary Tract Infections | 2015 |
Effect of food on the pharmacokinetics of canagliflozin/metformin (150/1,000 mg) immediate-release fixed-dose combination tablet in healthy participants.
Topics: Administration, Oral; Adolescent; Adult; Area Under Curve; Canagliflozin; Cross-Over Studies; Drug Combinations; Fasting; Female; Food-Drug Interactions; Glucosides; Half-Life; Healthy Volunteers; Humans; Hypoglycemic Agents; Male; Metabolic Clearance Rate; Metformin; Middle Aged; Postprandial Period; Tablets; Therapeutic Equivalency; Thiophenes; Young Adult | 2015 |
Efficacy, safety and tolerability of aleglitazar in patients with type 2 diabetes: pooled findings from three randomized phase III trials.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fasting; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin Resistance; Lipids; Male; Metformin; Middle Aged; Oxazoles; Sulfonylurea Compounds; Thiophenes | 2015 |
Efficacy and safety of ipragliflozin in Japanese patients with type 2 diabetes stratified by body mass index: A subgroup analysis of five randomized clinical trials.
Topics: Asian People; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Japan; Male; Metformin; Middle Aged; Pioglitazone; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Sulfonylurea Compounds; Thiazolidinediones; Thiophenes; Treatment Outcome | 2016 |
Efficacy, safety, and tolerability of ipragliflozin in Asian patients with type 2 diabetes mellitus and inadequate glycemic control with metformin: Results of a phase 3 randomized, placebo-controlled, double-blind, multicenter trial.
Topics: Asian People; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Humans; Male; Metformin; Thiophenes; Treatment Outcome | 2016 |
Efficacy and safety of ipragliflozin and metformin for visceral fat reduction in patients with type 2 diabetes receiving treatment with dipeptidyl peptidase-4 inhibitors in Japan: a study protocol for a prospective, multicentre, blinded-endpoint phase IV
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Intra-Abdominal Fat; Japan; Metformin; Prospective Studies; Research Design; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Tomography, X-Ray Computed; Treatment Outcome | 2017 |
Efficacy and safety of ipragliflozin as an add-on therapy to sitagliptin and metformin in Korean patients with inadequately controlled type 2 diabetes mellitus: A randomized controlled trial.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Male; Metformin; Middle Aged; Republic of Korea; Sitagliptin Phosphate; Thiophenes; Treatment Outcome; Young Adult | 2018 |
A phase 3 randomized placebo-controlled trial to assess the efficacy and safety of ipragliflozin as an add-on therapy to metformin in Russian patients with inadequately controlled type 2 diabetes mellitus.
Topics: Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Russia; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Treatment Outcome | 2018 |
Comparing the effects of ipragliflozin versus metformin on visceral fat reduction and metabolic dysfunction in Japanese patients with type 2 diabetes treated with sitagliptin: A prospective, multicentre, open-label, blinded-endpoint, randomized controlled
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Intra-Abdominal Fat; Japan; Male; Metformin; Middle Aged; Prospective Studies; Single-Blind Method; Sitagliptin Phosphate; Thiophenes; Treatment Outcome | 2019 |
Effects of ipragliflozin versus metformin in combination with sitagliptin on bone and muscle in Japanese patients with type 2 diabetes mellitus: Subanalysis of a prospective, randomized, controlled study (PRIME-V study).
Topics: Adult; Aged; Biomarkers; Blood Glucose; Bone and Bones; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Follow-Up Studies; Glucosides; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Muscles; Prognosis; Prospective Studies; Sitagliptin Phosphate; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Young Adult | 2021 |
A 52-week randomized controlled trial of ipragliflozin or sitagliptin in type 2 diabetes combined with metformin: The N-ISM study.
Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Sitagliptin Phosphate; Thiophenes; Treatment Outcome | 2021 |
A randomized, placebo-controlled trial to assess the efficacy and safety of sitagliptin in Japanese patients with type 2 diabetes and inadequate glycaemic control on ipragliflozin.
Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Glucosides; Glycated Hemoglobin; Glycemic Control; Humans; Hypoglycemic Agents; Japan; Metformin; Middle Aged; Sitagliptin Phosphate; Thiophenes; Treatment Outcome | 2021 |
Efficacy and safety of ipragliflozin in Japanese patients with type 2 diabetes and inadequate glycaemic control on sitagliptin.
Topics: Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Glucosides; Glycated Hemoglobin; Glycemic Control; Humans; Hypoglycemic Agents; Japan; Metformin; Middle Aged; Sitagliptin Phosphate; Thiophenes; Treatment Outcome | 2021 |
25 other study(ies) available for metformin and thiophenes
| Article | Year |
|---|---|
New therapeutic agents marketed in 1995.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acarbose; Alendronate; Anti-Inflammatory Agents; Anti-Ulcer Agents; Carbonic Anhydrase Inhibitors; Drug Approval; Enzyme Inhibitors; Hypoglycemic Agents; Lansoprazole; Metformin; Omeprazole; Pregnadienes; Sulfonamides; Thiophenes; Trisaccharides; United States; United States Food and Drug Administration | 1996 |
Identification and characterization of a small molecule AMPK activator that treats key components of type 2 diabetes and the metabolic syndrome.
Topics: AMP-Activated Protein Kinases; Animals; Biphenyl Compounds; Cell Line; Diabetes Mellitus, Type 2; Disease Models, Animal; Dose-Response Relationship, Drug; Enzyme Activation; Enzyme Activators; Fatty Acid Synthases; Glucose-6-Phosphatase; Hepatocytes; Humans; In Vitro Techniques; Metabolic Syndrome; Metformin; Mice; Mice, Obese; Molecular Weight; Multienzyme Complexes; Phosphoenolpyruvate Carboxykinase (GTP); Protein Serine-Threonine Kinases; Pyrones; Rats; Rats, Sprague-Dawley; RNA, Messenger; Thiophenes | 2006 |
The relationship between the drug concentration profiles in plasma and the drug doses in the colon.
Topics: Administration, Oral; Animals; Anti-Allergic Agents; Anti-Arrhythmia Agents; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Area Under Curve; Biological Availability; Colon; Delayed-Action Preparations; Diclofenac; Diltiazem; Dogs; Dose-Response Relationship, Drug; Hypoglycemic Agents; Metformin; Muscarinic Agonists; Quinuclidines; Terfenadine; Thiophenes; Verapamil | 2010 |
AMP-activated protein kinase regulates glucagon secretion from mouse pancreatic alpha cells.
Topics: Acetyltransferases; Adenosine Triphosphate; AMP-Activated Protein Kinases; Animals; Biphenyl Compounds; Blotting, Western; Calcium; Cell Line; Enzyme Activation; Female; Glucagon; Glucagon-Secreting Cells; Glucose; Hypoglycemic Agents; Immunohistochemistry; Metformin; Mice; Phenformin; Phosphorylation; Pyrones; Thiophenes | 2011 |
Activation of AMP-activated protein kinase (AMPK) provides a metabolic barrier to reprogramming somatic cells into stem cells.
Topics: AMP-Activated Protein Kinases; Animals; Biphenyl Compounds; Cellular Reprogramming; Fibroblasts; Humans; Hypoglycemic Agents; Induced Pluripotent Stem Cells; Kruppel-Like Factor 4; Kruppel-Like Transcription Factors; Metformin; Mice; Mice, Inbred C57BL; Octamer Transcription Factor-3; Proto-Oncogene Proteins c-myc; Pyrones; SOXB1 Transcription Factors; Thiophenes; Tumor Suppressor Protein p53 | 2012 |
Viewpoint: Central adjudication of myocardial infarction in outcome-driven clinical trials--common patterns in TRITON, RECORD, and PLATO?
Topics: Acute Coronary Syndrome; Adenosine; Cardiovascular Diseases; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Judgment; Metformin; Multicenter Studies as Topic; Myocardial Infarction; Observer Variation; Outcome Assessment, Health Care; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Process Assessment, Health Care; Randomized Controlled Trials as Topic; Rosiglitazone; Stroke; Sulfonylurea Compounds; Thiazolidinediones; Thiophenes; Ticagrelor | 2012 |
Involvement of the clock gene Rev-erb alpha in the regulation of glucagon secretion in pancreatic alpha-cells.
Topics: AMP-Activated Protein Kinases; Animals; Cell Line; Circadian Rhythm; Cytokines; Gene Expression Regulation; Glucagon; Glucagon-Secreting Cells; Glucose; Glycine; Isoquinolines; Metformin; Mice; Nicotinamide Phosphoribosyltransferase; Nuclear Receptor Subfamily 1, Group D, Member 1; RNA, Small Interfering; Signal Transduction; Sirtuin 1; Thiophenes | 2013 |
Differential effects of AMPK agonists on cell growth and metabolism.
Topics: Adenylate Kinase; Aminoimidazole Carboxamide; Animals; Biphenyl Compounds; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Glucose; HCT116 Cells; HEK293 Cells; Humans; Hypoglycemic Agents; Lactic Acid; Metformin; Mice; Neoplasms; Phenformin; Pyrones; Ribonucleotides; Sodium Salicylate; Thiophenes | 2015 |
The beneficial effects of AMP kinase activation against oxidative stress are associated with prevention of PPARα-cyclophilin D interaction in cardiomyocytes.
Topics: Adenylate Kinase; Animals; Antioxidants; Biphenyl Compounds; Cell Death; Cell Line; Cyclophilins; Dose-Response Relationship, Drug; Enzyme Activation; Enzyme Activators; Membrane Potential, Mitochondrial; Metformin; Mitochondria, Heart; Mitochondrial Membrane Transport Proteins; Mitochondrial Permeability Transition Pore; Myocytes, Cardiac; Oxidants; Oxidative Stress; PPAR alpha; Protein Binding; Protein Kinase Inhibitors; Pyrones; Rats; Reactive Oxygen Species; Signal Transduction; Thiophenes | 2015 |
Metformin synergizes 5-fluorouracil, epirubicin, and cyclophosphamide (FEC) combination therapy through impairing intracellular ATP production and DNA repair in breast cancer stem cells.
Topics: Adenosine Triphosphate; Aminoimidazole Carboxamide; AMP-Activated Protein Kinases; Antineoplastic Agents; Apoptosis; Biphenyl Compounds; Breast Neoplasms; Cyclophosphamide; DNA Damage; DNA Repair; Drug Combinations; Drug Synergism; Embryonic Stem Cells; Epirubicin; Female; Fibroblasts; Fluorouracil; Glucose; Humans; Hypoglycemic Agents; Lactic Acid; Lung; Metformin; Neoplastic Stem Cells; Pyrones; Ribonucleotides; Thiophenes | 2015 |
Effective impairment of myeloma cells and their progenitors by blockade of monocarboxylate transportation.
Topics: Cell Death; Cell Line, Tumor; Coumaric Acids; Gene Knockdown Techniques; Humans; Hydrogen-Ion Concentration; Metformin; Molecular Targeted Therapy; Monocarboxylic Acid Transporters; Multiple Myeloma; Muscle Proteins; Neoplastic Stem Cells; Symporters; Thiophenes; Uracil | 2015 |
Saponarin activates AMPK in a calcium-dependent manner and suppresses gluconeogenesis and increases glucose uptake via phosphorylation of CRTC2 and HDAC5.
Topics: AMP-Activated Protein Kinases; Apigenin; Benzimidazoles; Biphenyl Compounds; Calcium; Calcium-Calmodulin-Dependent Protein Kinase Kinase; Cyclic AMP Response Element-Binding Protein; Enzyme Activators; Forkhead Box Protein O1; Forkhead Transcription Factors; Gluconeogenesis; Glucose; Glucose Transporter Type 4; Glucosides; Hep G2 Cells; Histone Deacetylases; Humans; Insulin Resistance; Metformin; Naphthalimides; Phosphorylation; Pyrones; Thiophenes; Transcription Factors | 2015 |
A post-hoc analysis of the comparative efficacy of canagliflozin and glimepiride in the attainment of type 2 diabetes-related quality measures.
Topics: Aged; Blood Glucose; Blood Pressure Determination; Canagliflozin; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Quality Indicators, Health Care; Randomized Controlled Trials as Topic; Sulfonylurea Compounds; Thiophenes; Treatment Outcome | 2016 |
The AMPK Activator A769662 Blocks Voltage-Gated Sodium Channels: Discovery of a Novel Pharmacophore with Potential Utility for Analgesic Development.
Topics: AMP-Activated Protein Kinases; Analgesics; Anesthetics, Local; Animals; Binding Sites; Biphenyl Compounds; Drug Evaluation, Preclinical; HEK293 Cells; Hot Temperature; Humans; Male; meta-Aminobenzoates; Metformin; NAV1.7 Voltage-Gated Sodium Channel; Neural Conduction; Pain; Patch-Clamp Techniques; Pyrones; Rats; Rats, Sprague-Dawley; Reaction Time; Recombinant Fusion Proteins; Resveratrol; Sensory Receptor Cells; Sodium Channel Blockers; Stilbenes; Thiazoles; Thiophenes; Trigeminal Ganglion | 2017 |
AMPK activation reduces the number of atheromata macrophages in ApoE deficient mice.
Topics: Aminoimidazole Carboxamide; AMP-Activated Protein Kinases; Animals; Antigens, Ly; Aorta; Aortic Diseases; Apolipoproteins E; Atherosclerosis; Biphenyl Compounds; Cell Line; Cell Migration Inhibition; Chemotaxis; Disease Models, Animal; Enzyme Activation; Enzyme Activators; Genetic Predisposition to Disease; Humans; Macrophages; Metformin; Mice, Knockout; Phenotype; Pyrones; Receptors, CCR2; Ribonucleotides; Signal Transduction; Thiophenes | 2017 |
Combined treatment with Metformin and 2-deoxy glucose induces detachment of viable MDA-MB-231 breast cancer cells in vitro.
Topics: Aminoimidazole Carboxamide; AMP-Activated Protein Kinases; Biphenyl Compounds; Breast Neoplasms; Cell Adhesion; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxyglucose; Enzyme Activation; Female; Humans; Metformin; Pyrones; Ribonucleotides; Thiophenes | 2017 |
MCT1 Inhibitor AZD3965 Increases Mitochondrial Metabolism, Facilitating Combination Therapy and Noninvasive Magnetic Resonance Spectroscopy.
Topics: Acrylates; Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Cell Line, Tumor; Energy Metabolism; Female; HT29 Cells; Humans; Lactic Acid; Lymphoma; Magnetic Resonance Spectroscopy; Metformin; Mice, SCID; Mitochondria; Monocarboxylic Acid Transporters; Muscle Proteins; Pyrimidinones; Symporters; Thiophenes; Xenograft Model Antitumor Assays | 2017 |
AMPK Re-Activation Suppresses Hepatic Steatosis but its Downregulation Does Not Promote Fatty Liver Development.
Topics: Aminoimidazole Carboxamide; AMP-Activated Protein Kinases; Animals; Biphenyl Compounds; Cells, Cultured; Down-Regulation; Enzyme Activation; Fatty Acids; Fatty Liver; Gene Expression Regulation; Hepatocytes; Humans; Lipogenesis; Liver; Male; Metformin; Mice, Knockout; Oxidation-Reduction; Protein Serine-Threonine Kinases; Pyrones; Ribonucleotides; Small Molecule Libraries; Thiophenes | 2018 |
Investigation of Therapeutic Effects of Erdosteine on Polycystic Ovary Syndrome in a Rat Model.
Topics: Analysis of Variance; Animals; Blood Glucose; Cholesterol; Disease Models, Animal; Estrone; Expectorants; Female; Hypoglycemic Agents; Insulin Resistance; Metformin; Ovary; Oxidative Stress; Polycystic Ovary Syndrome; Random Allocation; Rats; Rats, Wistar; Thioglycolates; Thiophenes; Treatment Outcome; Uterus | 2018 |
Post-translational regulation of lipogenesis via AMPK-dependent phosphorylation of insulin-induced gene.
Topics: Animals; Biphenyl Compounds; Gene Expression Regulation; HEK293 Cells; Humans; Intracellular Signaling Peptides and Proteins; Lipogenesis; Membrane Proteins; Metformin; Mice; Mice, Knockout; Phosphorylation; Pyrones; Sterol Regulatory Element Binding Protein 1; Thiophenes; Ubiquitination | 2019 |
Ipragliflozin as an add-on therapy in type 2 diabetes mellitus patients: An evidence-based pharmacoeconomics evaluation.
Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Economics, Pharmaceutical; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2019 |
AMP-Kinase Dysfunction Alters Notch Ligands to Impair Angiogenesis in Neonatal Pulmonary Hypertension.
Topics: AMP-Activated Protein Kinase Kinases; Animals; Animals, Newborn; Biphenyl Compounds; Ductus Arteriosus; Electron Transport; Endothelial Cells; Enzyme Activation; Female; Hypertension, Pulmonary; Intracellular Signaling Peptides and Proteins; Jagged-1 Protein; Ligands; Lung; Membrane Proteins; Metformin; Mitochondria; Neovascularization, Pathologic; Persistent Fetal Circulation Syndrome; Phosphorylation; Pregnancy; Protein Kinases; Pyrones; Receptors, Notch; Sheep; Thiophenes; Threonine; Transfection | 2020 |
Glucose-lowering effects of 7-day treatment with SGLT2 inhibitor confirmed by intermittently scanned continuous glucose monitoring in outpatients with type 1 diabetes. A pilot study.
Topics: Adult; Ambulatory Care; Benzhydryl Compounds; Blood Glucose; Blood Glucose Self-Monitoring; Diabetes Mellitus, Type 1; Drug Therapy, Combination; Female; Glucosides; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Monitoring, Ambulatory; Pilot Projects; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2021 |
Transcriptome and lipidome profile of human mesenchymal stem cells with reduced senescence and increased trilineage differentiation ability upon drug treatment.
Topics: Ascorbic Acid; Cell Differentiation; Cellular Senescence; Humans; Hypoglycemic Agents; Lipidomics; Mesenchymal Stem Cells; Metformin; Pyrazines; Reverse Transcriptase Inhibitors; Sirolimus; Thiones; Thiophenes; Transcriptome | 2021 |
Pharmaceutical Drug Metformin and MCL1 Inhibitor S63845 Exhibit Anticancer Activity in Myeloid Leukemia Cells via Redox Remodeling.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cell Survival; Humans; Leukemia, Myeloid; Metformin; Myeloid Cell Leukemia Sequence 1 Protein; Oxidation-Reduction; Pyrimidines; Reactive Oxygen Species; Thiophenes | 2021 |